| Year |
Citation |
Score |
| 2020 |
Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients. Paediatric Drugs. PMID 32052309 DOI: 10.1007/S40272-020-00382-7 |
0.331 |
|
| 2020 |
Fuhr LM, Hanke N, Meibohm B, Lehr T. Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis. Clinical Pharmacokinetics. PMID 32020532 DOI: 10.1007/S40262-019-00857-Y |
0.302 |
|
| 2019 |
Shakhnovich V, Meibohm B, Rosenberg A, Kierzek AM, Hasenkamp R, Funk RS, Thalhauser CJ, van der Graaf PH, Wang YC, Hamuro L. Immunogenicity in Clinical Practice and Drug Development: When is it Significant? Clinical and Translational Science. PMID 31762152 DOI: 10.1111/Cts.12717 |
0.314 |
|
| 2019 |
Nagesh PKB, Chowdhury P, Hatami E, Kumari S, Kashyap VK, Tripathi MK, Wagh S, Meibohm B, Chauhan SC, Jaggi M, Yallapu MM. Cross linked polyphenol-based drug nano-self assemblies engineered to blockade prostate cancer senescence. Acs Applied Materials & Interfaces. PMID 31553876 DOI: 10.1021/Acsami.9B14738 |
0.306 |
|
| 2019 |
Walz A, Lukka PB, Pearce C, Creissen E, Braunstein M, Hickey AJ, Meibohm B, Gonzalez-Juarrero M. Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. Tuberculosis (Edinburgh, Scotland). 117: 52-55. PMID 31378268 DOI: 10.1016/J.Tube.2019.06.002 |
0.33 |
|
| 2019 |
Stewart IE, Lukka PB, Liu J, Meibohm B, Gonzalez-Juarrero M, Braunstein MS, Lee RE, Hickey AJ. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharmaceutical Research. 36: 136. PMID 31321552 DOI: 10.1007/S11095-019-2666-8 |
0.33 |
|
| 2019 |
Donnenberg VS, Chaikin P, Mandic M, Meibohm B, van den Anker J, Rhinehart E, Nafziger AN, Burris JF. Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them. Journal of Clinical Pharmacology. PMID 30768795 DOI: 10.1002/Jcph.1389 |
0.321 |
|
| 2019 |
Rathi C, Lukka PB, Wagh S, Lee RE, Lenaerts AJ, Braunstein M, Hickey A, Gonzalez-Juarrero M, Meibohm B. Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. Tuberculosis (Edinburgh, Scotland). 114: 119-122. PMID 30711150 DOI: 10.1016/J.Tube.2018.12.006 |
0.346 |
|
| 2018 |
Vaddady PK, Trivedi A, Rathi C, Madhura DB, Liu J, Lee RE, Meibohm B. Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. PMID 30419293 DOI: 10.1016/J.Ejps.2018.11.006 |
0.365 |
|
| 2018 |
Santos K, Lukka PB, Grzegorzewicz A, Jackson M, Trivedi A, Pavan F, Chorilli M, Braunstein M, Hickey A, Meibohm B, Gonzalez-Juarrero M. Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular . Frontiers in Microbiology. 9: 1895. PMID 30186246 DOI: 10.3389/Fmicb.2018.01895 |
0.335 |
|
| 2017 |
He H, Ma D, Crone LB, Butawan M, Meibohm B, Bloomer RJ, Yates CR. Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans. Journal of Caffeine Research. 7: 95-102. PMID 28875060 DOI: 10.1089/Jcr.2017.0006 |
0.337 |
|
| 2017 |
Siricilla S, Mitachi K, Yang J, Eslamimehr S, Lemieux MR, Meibohm B, Ji Y, Kurosu M. A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. Journal of Medicinal Chemistry. PMID 28291943 DOI: 10.1021/Acs.Jmedchem.6B01805 |
0.346 |
|
| 2017 |
Liu J, Bruhn DF, Lee RB, Zheng Z, Janusic T, Scherbakov D, Scherman MS, Boshoff HI, Das S, Rakesh, Waidyarachchi SL, Brewer TA, Gracia B, Yang L, Bollinger J, ... ... Meibohm B, et al. Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. Acs Infectious Diseases. 3: 72-88. PMID 28081607 DOI: 10.1021/Acsinfecdis.6B00158 |
0.35 |
|
| 2017 |
Herskovitz J, Ryman J, Thway T, Lee S, Zhou L, Chirmule N, Meibohm B, Jawa V. Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure. The Aaps Journal. PMID 28070711 DOI: 10.1208/S12248-016-0026-8 |
0.354 |
|
| 2016 |
Rathi C, Lee RE, Meibohm B. Translational PK/PD of anti-infective therapeutics. Drug Discovery Today. Technologies. 21: 41-49. PMID 27978987 DOI: 10.1016/J.Ddtec.2016.08.004 |
0.341 |
|
| 2016 |
Mould DR, Meibohm B. Drug Development of Therapeutic Monoclonal Antibodies. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 27342605 DOI: 10.1007/S40259-016-0181-6 |
0.351 |
|
| 2016 |
Leeder JS, Meibohm B. Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 44: 916-23. PMID 27302933 DOI: 10.1124/Dmd.116.071159 |
0.355 |
|
| 2016 |
Madhura DB, Trivedi A, Liu J, Boyd VA, Jeffries C, Loveless V, Lee RE, Meibohm B. Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis. The Aaps Journal. PMID 26984832 DOI: 10.1208/S12248-016-9900-7 |
0.332 |
|
| 2015 |
Gunn GR, Sealey DC, Jamali F, Meibohm B, Ghosh S, Shankar G. From the Bench to Clinical Practice: Understanding the Challenges and Uncertainties in Immunogenicity Testing for Biopharmaceuticals. Clinical and Experimental Immunology. PMID 26597698 DOI: 10.1111/Cei.12742 |
0.355 |
|
| 2015 |
Bruhn DF, Scherman MS, Liu J, Scherbakov D, Meibohm B, Böttger EC, Lenaerts AJ, Lee RE. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. Scientific Reports. 5: 13985. PMID 26365087 DOI: 10.1038/Srep13985 |
0.38 |
|
| 2015 |
Bruhn DF, Waidyarachchi SL, Madhura DB, Shcherbakov D, Zheng Z, Liu J, Abdelrahman YM, Singh AP, Duscha S, Rathi C, Lee RB, Belland RJ, Meibohm B, Rosch JW, Böttger EC, et al. Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. Science Translational Medicine. 7: 288ra75. PMID 25995221 DOI: 10.1126/Scitranslmed.3010572 |
0.351 |
|
| 2015 |
Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, Gupta M. Challenges and considerations for development of therapeutic proteins in pediatric patients. Journal of Clinical Pharmacology. 55: S103-15. PMID 25707958 DOI: 10.1002/Jcph.382 |
0.354 |
|
| 2014 |
Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS. The challenge of indication extrapolation for infliximab biosimilars. Biologicals : Journal of the International Association of Biological Standardization. 42: 177-83. PMID 24962198 DOI: 10.1016/J.Biologicals.2014.05.005 |
0.309 |
|
| 2014 |
Rakesh, Bruhn DF, Scherman MS, Woolhiser LK, Madhura DB, Maddox MM, Singh AP, Lee RB, Hurdle JG, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE. Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. Plos One. 9: e87909. PMID 24505329 DOI: 10.1371/Journal.Pone.0087909 |
0.315 |
|
| 2014 |
Lee RE, Hurdle JG, Liu J, Bruhn DF, Matt T, Scherman MS, Vaddady PK, Zheng Z, Qi J, Akbergenov R, Das S, Madhura DB, Rathi C, Trivedi A, Villellas C, ... ... Meibohm B, et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nature Medicine. 20: 152-8. PMID 24464186 DOI: 10.1038/Nm.3458 |
0.364 |
|
| 2013 |
Ramusovic S, Läer S, Meibohm B, Lagler FB, Paul T. Pharmacokinetics of intravenous amiodarone in children. Archives of Disease in Childhood. 98: 989-93. PMID 24051016 DOI: 10.1136/Archdischild-2013-304483 |
0.324 |
|
| 2013 |
Trivedi A, Lee RE, Meibohm B. Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert Review of Clinical Pharmacology. 6: 159-70. PMID 23473593 DOI: 10.1586/Ecp.13.6 |
0.312 |
|
| 2013 |
Bai JP, Barrett JS, Burckart GJ, Meibohm B, Sachs HC, Yao L. Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. The Aaps Journal. 15: 447-54. PMID 23334978 DOI: 10.1208/S12248-013-9452-Z |
0.31 |
|
| 2013 |
Thudium K, Bilic S, Leipold D, Mallet W, Kaur S, Meibohm B, Erickson H, Tibbitts J, Zhao H, Gupta M. American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. Mabs. 5: 5-12. PMID 23255090 DOI: 10.4161/Mabs.22909 |
0.338 |
|
| 2012 |
Rakesh, Bruhn D, Madhura DB, Maddox M, Lee RB, Trivedi A, Yang L, Scherman MS, Gilliland JC, Gruppo V, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE. Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorganic & Medicinal Chemistry. 20: 6063-72. PMID 22995771 DOI: 10.1016/J.Bmc.2012.08.023 |
0.331 |
|
| 2012 |
Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B. Physiologically Based Pharmacokinetic (PBPK) modeling in children Clinical Pharmacology and Therapeutics. 92: 40-49. PMID 22669290 DOI: 10.1038/Clpt.2012.64 |
0.347 |
|
| 2012 |
Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. The Aaps Journal. 14: 296-302. PMID 22407289 DOI: 10.1208/S12248-012-9340-Y |
0.352 |
|
| 2011 |
Meibohm B. Population pharmacokinetic/pharmacodynamic analyses as the basis for dosing of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 50: 823-4. PMID 22087868 DOI: 10.2165/11597950-000000000-00000 |
0.31 |
|
| 2011 |
Budha NR, Kovar A, Meibohm B. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. The Aaps Journal. 13: 650-61. PMID 22005901 DOI: 10.1208/S12248-011-9302-9 |
0.672 |
|
| 2011 |
Prado ME, Ryman JT, Boileau MJ, Martin-Jimenez T, Meibohm B. Pharmacokinetics of ponazuril after oral administration to healthy llamas (Lama glama). American Journal of Veterinary Research. 72: 1386-9. PMID 21962282 DOI: 10.2460/Ajvr.72.10.1386 |
0.307 |
|
| 2011 |
Vaddady PK, Mehrotra N, Zhang X, Yates CR, Moore BM, Meibohm B. Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock. Biopharmaceutics & Drug Disposition. 32: 89-98. PMID 21341278 DOI: 10.1002/Bdd.740 |
0.304 |
|
| 2010 |
Suryawanshi S, Zhang L, Pfister M, Meibohm B. The current role of model-based drug development. Expert Opinion On Drug Discovery. 5: 311-21. PMID 22823084 DOI: 10.1517/17460441003713470 |
0.334 |
|
| 2010 |
Vaddady PK, Lee RE, Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Medicinal Chemistry. 2: 1355-69. PMID 21359155 DOI: 10.4155/Fmc.10.224 |
0.404 |
|
| 2010 |
Chen J, Wang Z, Li CM, Lu Y, Vaddady PK, Meibohm B, Dalton JT, Miller DD, Li W. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. Journal of Medicinal Chemistry. 53: 7414-27. PMID 20919720 DOI: 10.1021/Jm100884B |
0.311 |
|
| 2010 |
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 49: 633-59. PMID 20818831 DOI: 10.2165/11535960-000000000-00000 |
0.709 |
|
| 2009 |
Budha NR, Lee RB, Hurdle JG, Lee RE, Meibohm B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinburgh, Scotland). 89: 378-85. PMID 19748318 DOI: 10.1016/J.Tube.2009.08.002 |
0.693 |
|
| 2009 |
Läer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. Journal of Clinical Pharmacology. 49: 889-904. PMID 19531673 DOI: 10.1177/0091270009337513 |
0.346 |
|
| 2008 |
Dirks NL, Li S, Huth B, Hochhaus G, Yates CR, Meibohm B. Transrepression and transactivation potencies of inhaled glucocorticoids. Die Pharmazie. 63: 893-8. PMID 19177906 DOI: 10.1691/Ph.2008.8638 |
0.69 |
|
| 2008 |
Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. The Aaps Journal. 10: 552-9. PMID 19003542 DOI: 10.1208/S12248-008-9062-3 |
0.349 |
|
| 2008 |
Zhang Y, Mehrotra N, Budha NR, Christensen ML, Meibohm B. A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens. Clinica Chimica Acta; International Journal of Clinical Chemistry. 398: 105-12. PMID 18796299 DOI: 10.1016/J.Cca.2008.08.023 |
0.654 |
|
| 2008 |
Mertens-Talcott SU, Rios J, Jilma-Stohlawetz P, Pacheco-Palencia LA, Meibohm B, Talcott ST, Derendorf H. Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers. Journal of Agricultural and Food Chemistry. 56: 7796-802. PMID 18693743 DOI: 10.1021/Jf8007037 |
0.303 |
|
| 2008 |
Hurdle JG, Lee RB, Budha NR, Carson EI, Qi J, Scherman MS, Cho SH, McNeil MR, Lenaerts AJ, Franzblau SG, Meibohm B, Lee RE. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. The Journal of Antimicrobial Chemotherapy. 62: 1037-45. PMID 18693235 DOI: 10.1093/Jac/Dkn307 |
0.671 |
|
| 2008 |
Budha NR, Mehrotra N, Tangallapally R, Rakesh, Qi J, Daniels AJ, Lee RE, Meibohm B. Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. The Aaps Journal. 10: 157-65. PMID 18446516 DOI: 10.1208/S12248-008-9017-8 |
0.679 |
|
| 2008 |
Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Current Medicinal Chemistry. 15: 809-25. PMID 18393850 DOI: 10.2174/092986708783955509 |
0.697 |
|
| 2008 |
Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. Journal of Clinical Pharmacology. 48: 267-78. PMID 18218786 DOI: 10.1177/0091270007313393 |
0.706 |
|
| 2007 |
Tangallapally RP, Sun D, Rakesh, Budha N, Lee RE, Lenaerts AJ, Meibohm B, Lee RE. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorganic & Medicinal Chemistry Letters. 17: 6638-42. PMID 17937983 DOI: 10.1016/J.Bmcl.2007.09.048 |
0.677 |
|
| 2007 |
Chen ML, Straughn AB, Sadrieh N, Meyer M, Faustino PJ, Ciavarella AB, Meibohm B, Yates CR, Hussain AS. A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharmaceutical Research. 24: 73-80. PMID 17048115 DOI: 10.1007/S11095-006-9120-4 |
0.338 |
|
| 2007 |
Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. International Journal of Impotence Research. 19: 253-64. PMID 16988721 DOI: 10.1038/Sj.Ijir.3901522 |
0.395 |
|
| 2006 |
Tang L, Meibohm B. Pharmacokinetics of Peptides and Proteins Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. 15-43. DOI: 10.1002/3527600906.Mcb.200400105.Pub2 |
0.314 |
|
| 2006 |
Meibohm B, Derendorf H. Pharmacokinetics and Pharmacodynamics of Biotech Drugs Reviews in Cell Biology and Molecular Medicine. 145-172. DOI: 10.1002/3527600906.Mcb.200400105 |
0.384 |
|
| 2005 |
Song P, Meibohm B, Yates CR. LC/MS/MS in drug development: targeting the brain. Biotechniques. 19-23. PMID 16528912 DOI: 10.2144/05386Su03 |
0.339 |
|
| 2005 |
Meibohm B, Läer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. The Aaps Journal. 7: E475-87. PMID 16353925 DOI: 10.1208/Aapsj070248 |
0.309 |
|
| 2005 |
Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. Journal of Clinical Pharmacology. 45: 987-1003. PMID 16100293 DOI: 10.1177/0091270005276847 |
0.366 |
|
| 2005 |
LAER S, ALBERS S, GUPTA M, MIR T, MEIBOHM B. Population pharmacokinetics of carvedilol in pediatric patients with congestive heart failure Clinical Pharmacology & Therapeutics. 77: P88-P88. DOI: 10.1016/J.Clpt.2004.12.229 |
0.312 |
|
| 2004 |
Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. International Journal of Clinical Pharmacology and Therapeutics. 42: 701-18. PMID 15624287 |
0.703 |
|
| 2004 |
Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. Journal of Pharmaceutical Sciences. 93: 2184-204. PMID 15295780 DOI: 10.1002/Jps.20125 |
0.357 |
|
| 2003 |
Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR, Alloway RR, Meibohm B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. Journal of Clinical Pharmacology. 43: 555-64. PMID 12817518 DOI: 10.1177/0091270003253617 |
0.318 |
|
| 2002 |
Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clinical Pharmacokinetics. 41: 329-42. PMID 12036391 DOI: 10.2165/00003088-200241050-00002 |
0.333 |
|
| 2002 |
Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. Journal of Pharmaceutical Sciences. 91: 18-31. PMID 11782894 DOI: 10.1002/Jps.1167 |
0.368 |
|
| 1999 |
Meibohm B, Hochhaus G, Möllmann H, Barth J, Wagner M, Krieg M, Stöckmann R, Derendorf H. A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids Journal of Pharmacokinetics and Biopharmaceutics. 27: 127-147. PMID 10567952 DOI: 10.1023/A:1020670421957 |
0.342 |
|
| 1999 |
Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives Pharmaceutical Research. 16: 176-185. PMID 10100300 DOI: 10.1023/A:1011907920641 |
0.35 |
|
| 1998 |
Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids Journal of Allergy and Clinical Immunology. 101. PMID 9563369 DOI: 10.1016/S0091-6749(98)70156-3 |
0.316 |
|
| 1998 |
Möllmann H, Wagner M, Meibohm B, Hochhaus G, Barth J, Stöckmann R, Krieg M, Weisser H, Falcoz C, Derendorf H. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration European Journal of Clinical Pharmacology. 53: 459-467. PMID 9551705 DOI: 10.1007/S002280050407 |
0.339 |
|
| 1997 |
Möllmann H, Derendorf H, Barth J, Meibohm B, Wagner M, Krieg M, Weisser H, Knöller J, Möllmann A, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation Journal of Clinical Pharmacology. 37: 893-903. PMID 9505980 DOI: 10.1002/J.1552-4604.1997.Tb04263.X |
0.359 |
|
| 1997 |
Meibohm B, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Wagner M, Krieg M, Stöckmann R, Derendorf H. Dependency of cortisol suppression on administration time of inhaled corticosteroids Journal of Clinical Pharmacology. 37: 704-710. PMID 9378842 DOI: 10.1002/J.1552-4604.1997.Tb04357.X |
0.34 |
|
| 1996 |
Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Möllmann H, Derendorf H. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate Journal of Clinical Pharmacology. 36: 938-941. PMID 8930781 DOI: 10.1002/J.1552-4604.1996.Tb04761.X |
0.344 |
|
| Show low-probability matches. |